Immunotherapy with peptides

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 66, Issue 6, 2011, Pages 784-791

  Moldaver, D ^a   Larche M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

epitope; immune tolerance; peptide; regulation; T cell

Indexed keywords

ALLERGEN; ALLERVAXCAT; BEE VENOM; IMMUNOMODULATING AGENT; PEPTIDE API M 1; PEPTIDE IPC 1; PEPTIDE IPC 2; PLACEBO; POLYPEPTIDE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ALLERGY; ASTHMA; AUTOIMMUNE DISEASE; CHEST TIGHTNESS; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ERYTHEMA; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; T LYMPHOCYTE;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES, B-LYMPHOCYTE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNE TOLERANCE; INTERLEUKIN-10; MICE; PEPTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 79955478697     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02610.x     Document Type: Review

References (55)

1. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al., Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-475. (Pubitemid 29372886)
2. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al., Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-948. (Pubitemid 47037870)
3. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S,. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31: 1392-1397. (Pubitemid 32823876)
4. Larche M, Akdis CA, Valenta R,. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6: 761-771. (Pubitemid 44453462)
5. Larche M, Wraith DC,. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11 (4 Suppl.): S69-S76. (Pubitemid 40562306)
6. Larche M,. Peptide immunotherapy for allergic diseases. Allergy 2007; 62: 325-331.
7. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M,. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983; 157: 1434-1447. (Pubitemid 13088987)
8. Warrens AN, Zhang JY, Sidhu S, Watt DJ, Lombardi G, Sewry CA, et al., Myoblasts fail to stimulate T cells but induce tolerance. Int Immunol 1994; 6: 847-853. (Pubitemid 24183319)
9. Bal V, McIndoe A, Denton G, Hudson D, Lombardi G, Lamb J, et al., Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990; 20: 1893-1897. (Pubitemid 20355608)
10. Lombardi G, Sidhu S, Batchelor R, Lechler R,. Anergic T cells as suppressor cells in vitro. Science 1994; 264: 1587-1589. (Pubitemid 24227713)
11. Gammon G, Dunn K, Shastri N, Oki A, Wilbur S, Sercarz EE,. Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation. Nature 1986; 319: 413-415. (Pubitemid 16163902)
12. Clayton JP, Gammon GM, Ando DG, Kono DH, Hood L, Sercarz EE,. Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein. J Exp Med 1989; 169: 1681-1691. (Pubitemid 19126825)
13. Critchfield JM, Racke MK, Zuniga-Pflucker JC, Cannella B, Raine CS, Goverman J, et al., T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994; 263: 1139-1143. (Pubitemid 24105960)
14. Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG,. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992; 258: 1491-1494. (Pubitemid 23011006)
15. Metzler B, Wraith DC,. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 1993; 5: 1159-1165. (Pubitemid 23291165)
16. Ku G, Kronenberg M, Peacock DJ, Tempst P, Banquerigo ML, Braun BS, et al., Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen. Eur J Immunol 1993; 23: 591-599. (Pubitemid 23095089)
17. Staines NA, Harper N, Ward FJ, Malmstrom V, Holmdahl R, Bansal S,. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol 1996; 103: 368-375. (Pubitemid 26089942)
18. Prakken BJ, van Der ZR, Anderton SM, van Kooten PJ, Kuis W, van Eden W,. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci U S A 1997; 94: 3284-3289.
19. Daniel D, Wegmann DR,. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996; 93: 956-960. (Pubitemid 26041202)
20. Bockova J, Elias D, Cohen IR,. Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies. J Autoimmun 1997; 10: 323-329. (Pubitemid 27366137)
21. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, et al., Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183: 1561-1567. (Pubitemid 26134299)
22. Burkhart C, Liu GY, Anderton SM, Metzler B, Wraith DC,. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int Immunol 1999; 11: 1625-1634. (Pubitemid 29481729)
23. Anderton SM, Burkhart C, Liu GY, Metzler B, Wraith DC,. Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease. Novartis Found Symp 1998; 215: 120-131.
24. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR,. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993; 178: 1783-1788. (Pubitemid 23318458)
25. Bauer L, Bohle B, Jahn-Schmid B, Wiedermann U, Daser A, Renz H, et al., Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol 1997; 107: 536-541. (Pubitemid 27102143)
26. King TP, Lu G, Agosto H,. Antibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell epitope peptides. J Allergy Clin Immunol 1998; 101: 397-403. (Pubitemid 28146361)
27. von Garnier C, Astori M, Kettner A, Dufour N, Heusser C, Corradin G, et al., Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol 2000; 30: 1638-1645. (Pubitemid 30342806)
28. Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL,. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci U S A 1993; 90: 7608-7612. (Pubitemid 23249999)
29. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, Stern LJ, et al., Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009; 206: 1535-1547.
30. Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, et al., Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009; 155: 156-165.
31. Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, et al., Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004; 101: 4228-4233. (Pubitemid 38405911)
32. Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, et al., Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum 2009; 60: 3207-3216.
33. Norman PS, Ohman JL, Long AA, Creticos PS, Gefter MA, Shaked Z, et al., Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154 (6 Pt 1): 1623-1628. (Pubitemid 26424925)
34. Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sobotka A, Lichtenstein LM, et al., Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998; 101 (4 Pt 1): 506-513. (Pubitemid 28208255)
35. Haselden BM, Kay AB, Larche M,. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999; 189: 1885-1894. (Pubitemid 29295887)
36. Pene J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF, et al., Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998; 102 (4 Pt 1): 571-578. (Pubitemid 28487932)
37. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT,. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999; 93: 222-231.
38. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT,. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8: 1937-1945. (Pubitemid 27007744)
39. Oldfield WL, Kay AB, Larche M,. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001; 167: 1734-1739. (Pubitemid 32703177)
40. Oldfield WL, Larche M, Kay AB,. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360: 47-53. (Pubitemid 34756492)
41. Alexander C, Ying S, Kay B, Larche M,. Fel d 1-derived T cell peptide therapy induces recruitment of CD4CD25; CD4 interferon-gamma T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005; 35: 52-58. (Pubitemid 40188270)
42. Alexander C, Tarzi M, Larche M, Kay AB,. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60: 1269-1274. (Pubitemid 41297523)
43. Smith TR, Alexander C, Kay AB, Larche M, Robinson DS,. Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25 T cells: a double-blind placebo-controlled study. Allergy 2004; 59: 1097-1101. (Pubitemid 39279108)
44. Verhoef A, Alexander C, Kay AB, Larche M,. T cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity. PLoS Med 2005; 2: e78.
45. Haselden BM, Syrigou E, Jones M, Huston D, Ichikawa K, Chapman MD, et al., Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1. J Allergy Clin Immunol 2001; 108: 349-356. (Pubitemid 32881054)
46. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, et al., Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011; 127: 89-97.
47. Carballido JM, Carballido-Perrig N, Kagi MK, Meloen RH, Wuthrich B, Heusser CH, et al., T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol 1993; 150 (8 Pt 1): 3582-3591. (Pubitemid 23129739)
48. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, et al., Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101 (6 Pt 1): 747-754.
49. Texier C, Pouvelle S, Busson M, Herve M, Charron D, Menez A, et al., HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000; 164: 3177-3184. (Pubitemid 30148979)
50. Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, et al., Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36: 465-474.
51. Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, et al., Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111: 854-861. (Pubitemid 36470260)
52. Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY,. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998; 160: 3555-3561. (Pubitemid 28164751)
53. Steinman RM, Hawiger D, Nussenzweig MC,. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711. (Pubitemid 37174545)
54. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al., Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199: 1567-1575. (Pubitemid 38780411)
55. Tree TI, Lawson J, Edwards H, Skowera A, Arif S, Roep BO, et al., Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 2010; 59: 1451-1460.